Remove Capital Market Remove Collaboration Remove Medical
article thumbnail

A Lookback: Tyton Partners Last 50 Transactions + Key Deal Takeaways

Tyton Partners

Achieve Partners’ social impact focus and deep experience in the digital transformation of education makes them the perfect partner for Elentra to continue to scale its purpose-built platform, and acquire other solutions, to best serve medical and allied health institutions globally.

article thumbnail

2024 Key Deal Highlights and Predictions for 2025

Tyton Partners

K-12 Transaction Spotlight The K-12 education market is undergoing a significant transformation in the post-COVID era, driven by the expiration of federal Elementary and Secondary School Emergency Relief (ESSER) funds. We wish you a prosperous New Year and look forward to the opportunity to collaborate with you in the near future.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40
article thumbnail

Cooley’s 2019 Life Sciences M&A Year in Review

Cooley M&A

A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 Year of the Life Sciences Mega-Deals. billion acquisition of The Medicines Company.

M&A 40